关节腔内抗生素输注对比静脉抗生素给药治疗感染性膝关节置换:随机多中心临床试验研究方案
本研究为一项实用型、多中心、两臂、平行组、开放、随机非劣效性试验(非劣效界值-15%),纳入142例全膝关节置换术后假体周围感染并接受一期翻修的患者,1:1随机分配至关节腔内抗生素输注组或静脉抗生素给药组,随访2年,主要结局为感染控制率。
要点
- 比较关节腔内输注与静脉抗生素在感染性膝关节置换中的感染控制率。
- 设计为随机、多中心、开放、非劣效性试验,非劣效界值-15%。
- 纳入142例全膝关节置换术后假体周围感染行一期翻修患者,随访2年。
核心结论
- 若关节腔内抗生素输注在感染控制率上不劣于传统静脉给药,且肝肾功能损伤更少、并发症更少、抗生素用量更少,则作者认为该给药方式应在假体周围膝关节感染治疗中进一步提倡。
研究设计与样本
- 实用型、多中心、两臂、平行组、开放、随机非劣效性试验,非劣效界值-15%。
- 涉及11个高容量三级转诊中心,1:1分配。
- 142例全膝关节置换术后假体周围感染并接受一期翻修的患者随机分配至关节腔内或静脉抗生素组。
- 因干预性质无法设盲,但数据收集者和统计分析者保持盲态。
- 所有患者随访2年。
主要发现
- 主要结局为感染控制率。
- 次要结局包括功能结局、外周血和关节液中抗生素浓度、肝肾功能损伤、再手术率及两组抗生素使用情况。
关键数值与推荐
- 非劣效界值为-15%。
- 主要结局为感染控制率,随访2年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因干预性质无法对受试者和干预实施者设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Periprosthetic joint infection (PJI) poses a formidable challenge following total joint arthroplasty (TJA). Whether using Debridement, Antibiotics, and Implant Retention (DAIR) for acute cases or one/two-stage revision for chronic scenarios, postoperative antibiotics administered intravenously is standard. However, this delivery method inevitably risks hepatic and renal function impairment, lacking a sufficiently minimal biofilm eradication concentration. Intra-articular infusion as a novel antibiotic delivery method can circumvent systemic circulation, reduce the risk of hepatic and renal function impairment, and provide a sufficiently high antibiotic concentration at the prosthetic infection site. Yet, the efficacy of these methods has never been evaluated in a randomized controlled trial. The study aims to investigate infection control rates within 2 years post intra-articular antibiotic infusion versus intravenous antibiotic administration in a randomized design. METHODS: This pragmatic, multicenter, two-armed, parallel group, open, randomized non-inferiority trial (non-inferiority margin-15%) involves 11 high-volume tertiary referral centers (1:1 allocation). One hundred forty-two eligible PJI patients following total knee arthroplasty, undergoing one-stage revision, were randomly assigned to intra-articular or intravenous antibiotics. Blinding is not possible due to the nature of the intervention. However, data collectors and statistical analysts remain blind to the groups. All patients will be followed up for 2 years. The primary outcome is the infection control rate, and the secondary outcomes include functional outcome, concentrations of antibiotics in peripheral blood and joint fluid, along with liver and kidney injury, the reoperation rate, and antibiotic usage for both patient groups. DISCUSSION: This is the first randomized controlled trial to compare the efficacy of intra-articular antibiotic infusions and intravenous antibiotic administration. If intra-articular antibiotic infusion demonstrates non-inferiority in infection control rate compared to traditional intravenous antibiotic administration, with lower rates of hepatic and renal impairment, fewer complications, and reduced antibiotic usage, then this mode of drug administration should be further advocated in the treatment of periprosthetic knee infections. The results of the trial will benefit patients, clinicians, and overall healthcare resource utilization. TRIAL REGISTRATION: The randomized trial is registered on https://www.chictr.org.cn/showproj.html?proj=36750 with ID ChiCTR1900022102, initial release date March 25, 2019.
引用
- Ji B, Li Y, Yan X, et al. Intra-articular antibiotic infusions versus intravenous antibiotic administration for infected knee arthroplasty: a study protocol for a randomized multicenter clinical trial. Trials. 2025. PMID: 41390465. doi:10.1186/s13063-025-09319-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。